Dispense Sample Clauses

Dispense. The placing of one or more doses of a prescribed medication into containers that are correctly labeled to indicate the name of the offender, the contents of the container, and all other vital information.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Dispense approximately 1 mL of REP Prep onto the left side of the rectangle on the electrophoresis chamber floor.
Sample 1Sample 2
Dispense pharmaceutical drugs to Xxxxxx Health Fund members that provide coherent prescription and membership details in line with the Xxxxxx Health Fund plans as denoted either on the members’ card or on the Holistic Insurance Platform (HiP) portal. The five generic plans are MAIN/SCHEME, USD, INDEXED, USD FUNDS and FUNDS.
Sample 1
Dispense. [Confidential Treatment Requested] of sample into [Confidential Treatment Requested] coated tube 2. Add [Confidential Treatment Requested] solution and vortex 3. Incubate for [Confidential Treatment Requested] 4. Aspirate and wash [Confidential Treatment Requested] with wash solution 5. Add [Confidential Treatment Requested] of [Confidential Treatment Requested] solution 6. Incubate for [Confidential Treatment Requested] 7. Aspirate and wash [Confidential Treatment Requested] 8. Measure tubes for [Confidential Treatment Requested] in [Confidential Treatment Requested] Limit of detection: [Confidential Treatment Requested] TgAb activity Precision: [Confidential Treatment Requested] CV intra-assay over range Range: [Confidential Treatment Requested] U/ml IMMUNOCHEMILUMINOMETRIC ASSAY FOR THYROID PEROXIDASE ANTIBODIES INTRODUCTION Autoimmune thyroid disease is characterized by the production of antibodies to various thyroid proteins. Thyroid peroxidase (TPO) is one such protein and the detection of circulating antibodies to TPO is indicative of thyroid autoimmunity.
Sample 1
Dispense approximately 1 mL of REP Prep onto the cathode (left) side of the electrophoresis chamber.
Sample 1
Dispense about 1 mL of REP Prep onto the left side of the marked area of the chamber.
Sample 1
Dispense. Dispense Pharmaceuticals as set out in Orders utilizing one of the following types of packaging: (i) blister cards for all oral, solid dosage forms (tablets and capsules), including utilization of Unit Dose packaging where required for the return and re-use of Pharmaceuticals; (ii) liquid, oral medications will be dispensed in bulk form unless another format is mandated by the appropriate PHS medical staff and agreed upon between Maxor and PHS; (iii) injectable medications; and (iv) special packaging as requested by the appropriate PHS medical staff and agreed upon by Maxor.
Sample 1
AutoNDA by SimpleDocs
Dispense. [Confidential Treatment Requested] test sample or control into each well
Sample 1
Dispense. [Confidential Treatment Requested] of serum sample into tube 2) Add [Confidential Treatment Requested] of receptor solution 3) Incubate [Confidential Treatment Requested] at [Confidential Treatment Requested] 4) Add [Confidential Treatment Requested] of [Confidential Treatment Requested] labeled [Confidential Treatment Requested] solution 5) Incubate [Confidential Treatment Requested] 6) Add [Confidential Treatment Requested] solution, vortex 7) Centrifuge for [Confidential Treatment Requested] at [Confidential Treatment Requested] 8). Aspirate supernatant 9) Resuspend pellet in [Confidential Treatment Requested] deionized water 10) Measure tubes for [Confidential Treatment Requested] in [Confidential Treatment Requested] Limit of detection: [Confidential Treatment Requested] TRAb activity Precision: [Confidential Treatment Requested] intra-assay over range Range: [Confidential Treatment Requested] U/ml SCHEDULE B Page ___ SCHEDULE B UWCM PATENTS CASE WCM 3: LUMINESCENT PROTEIN LABELING COUNTRY PATENT # FILED PRIORITY EXPIRY ------- -------- ----- -------- ------ GB 2008247B 14/11/78 17/11/77 14/11/98 Canada 1113392 16/11/78 17/11/77 01/12/98 Germany 2849708 16/11/78 17/11/77 Lapsed Switzerland 640061 13/11/78 17/11/77 13/11/98 France 7832459 17/11/78 17/11/77 17/11/98 USA 4478817 14/11/78 17/11/77 23/10/01 CASE WCM 3 (DIVISIONAL) HOMOGENEOUS ASSAY COUNTRY PATENT # FILED PRIORITY EXPIRY ------- -------- ----- -------- ------ GB 2095830B 01/11/81 17/11/77 14/11/98 Germany 2858792 07/06/89 17/11/77 17/11/98 Switzerland 645725 13/12/83 17/11/77 13/11/98 Canada 1116079 27/3/81 17/11/77 12/01/99 CASE WCM 13: ACRIDINIUM LABELS COUNTRY PATENT # FILED PRIORITY EXPIRY ------- -------- ----- -------- ------ GB 2112779B 08/12/82 11/12/81 08/12/02 Europe* 0082636 08/12/82 11/12/81 08/12/02 USA# 4946958 26/09/88 11/12/81 07/08/07 CASE WCM 16: MASS PHOTON IMMUNOASSAY COUNTRY PATENT # FILED PRIORITY EXPIRY ------- -------- ----- -------- ------ GB 2129553B 09/09/83 10/09/82 09/09/03 Europe** 0103469 09/09/83 10/09/82 09/09/03 USA 4761382 05/02/87 10/09/82 02/08/05 Japan Pending 29/12/83 10/09/82 29/12/03 *France, Germany, Holland, Switzerland **Belgium, France, Germany, Italy, Holland, Switzerland UWCM PATENT APPLICATIONS #US Continuation Applications 08/328563 filed 24/10/94 and 08/455414 filed 31/05/95 are still pending. BIOANALYSIS PATENTS None BIOANALYSIS PATENT APPLICATIONS None
Sample 1

Related to Dispense

  • Packing 9.1 The supplier shall provide such packing of the goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in the contract. The packing shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt and precipitation during transit, and open storage. Packing, case size and weights shall take into consideration, where appropriate, the remoteness of the goods’ final destination and the absence of heavy handling facilities at all points in transit.

  • Samples The Contractor shall submit the following samples of Materials and relevant information to the Authority’s Engineer for pre-construction review:

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

  • Shipment Dell will ship the APEX System to the Site when included as part of the APEX Service. The terms and process for shipment and delivery of the APEX System will be stated in the applicable Service Offering Description.

  • Packaging Tangible product shall be securely and properly packed for shipment, storage, and stocking in appropriate, clearly labeled, shipping containers and according to accepted commercial practice, without extra charge for packing materials, cases, or other types of containers. All containers and packaging shall become and remain Customer’s property.

  • Licensure The Contractor covenants that it has:

  • Products Products available under this Contract are limited to Software, including Software as a Service, products and related products as specified in Appendix C, Pricing Index. Vendor may incorporate changes to their product offering; however, any changes must be within the scope of products awarded based on the posting described in Section 1.B above. Vendor may not add a manufacturer’s product line which was not included in the Vendor’s response to the solicitation described in Section 1.B above.

Time is Money Join Law Insider Premium to draft better contracts faster.